Castle Biosciences Q3 2026 Earnings Call - CASTLE BIOSCIENCES INC

Financial Performance:

• Third quarter 2026 revenue reached $102.9 million, representing 24% year-over-year growth.
• Gross margin held steady at 75%, with adjusted gross margin at 77%, driven by operational efficiencies and consistent unpaid test volumes.
• Net loss narrowed to $4.1 million ($0.13 diluted loss per share) compared to $5.0 million in the prior year period, despite higher operating expenses.
• Adjusted EBITDA improved to $12.7 million, up from $9.2 million in Q3 2025, reinforcing a path to profitability.
• Operating cash flow was strong at $19.7 million for the quarter, with total cash, cash equivalents, and marketable securities totaling $278 million.
• Operating expenses rose to $105.6 million (up from $89.8 million) due to increased headcount in commercial teams, IT costs, and higher lab supplies/services to support volume growth.

Guidance and Future Outlook:

• Full-year 2026 total revenue guidance was raised to $385–$395 million (previously $365–$375 million), reflecting a $20 million midpoint increase driven by TissueCypher volume and ASP improvements.
• Full-year 2026 TissueCypher test report growth is expected to be 50–52%.
• DecisionDx Melanoma full-year volume growth is now expected to be mid-single digits, down from previous higher estimates.
• Management expects positive adjusted EBITDA for Q4 2026 and the full years of 2026 and 2027.
• 2027 revenue planning assumes no immediate recovery of Medicare coverage for DecisionDx SCC; recovery is factored into 2028 plans.

Business Segments and Product Lines:

• TissueCypher: Delivered 15,574 reports in Q3 (47% YoY growth); currently estimated at 15% penetration of eligible endoscopy procedures; recent clinical study in Annals of Gastroenterology highlights improved patient management outcomes.
• DecisionDx Melanoma: Achieved 10,177 reports, marking the fifth consecutive quarter exceeding 10,000 reports; remains the primary focus of the dermatology commercial team.
• Advanced ADTX: Reported 1,109 tests; new real-world data shows 98% alignment between test results and systemic treatment changes, with high patient interest in molecular testing.
• DecisionDx SCC: Volumes remain under pressure due to lack of Medicare coverage; no new growth assumptions included for 2027.
• EZOpredict: Successfully pivoted to cases where TissueCypher tissue quality is insufficient, capturing additional value within the Barrett's esophagus workflow.

Market and Competitive Landscape:

• TissueCypher market penetration is early-stage, leaving significant room for growth as payers and clinicians recognize clinical utility in risk-aligned management.
• Management noted that while seasonality exists (e.g., Q4 holiday disruption), strong growth trends are outpacing these seasonal fluctuations.
• CMS proposed "gap fill" pricing for Advanced ADTX instead of the advisory panel's recommended crosswalk to existing NG-based tests; Castle submitted comments and expects final determination in December.
• Sales force headcount for both TissueCypher and Dermatology teams remains around 100, deemed sufficient for current growth trajectories.

Risks and Challenges:

• Regulatory/Payer Risks: Uncertainty remains regarding CMS finalization of ADTX pricing and the timeline for recovering Medicare coverage for DecisionDx SCC.
• Operational Scaling: Lab headcount and costs will likely continue to rise in tandem with test volumes, though efficiencies are expected to mitigate some pressure.
• Sales Force Dislocations: Recent expansions in the TissueCypher sales team have caused minor short-term coverage bumps, though long-term capacity is being built.
• Market Competition: While no specific competitors were named, the commentary highlights the need to demonstrate economic benefit to payers to secure ASP gains.

Management Commentary and Tone:

• Tone is confident and optimistic, emphasizing "disciplined expense management" and "focused execution."
• Management highlighted the clinical value of their tests as the primary driver of adoption and financial resilience.
• Derek Massold (CEO) expressed satisfaction with the core business momentum and the strategic integration of acquired assets like EZOpredict.
• Frank Stokes (CFO) highlighted the durability of gross margins and the flexibility provided by the strong balance sheet ($278M cash).

Analyst Questions and Answers:

• Q4 Outlook: Implied Q4 guidance is strong but seasonally lighter than Q3 due to year-end practice closures; management expects core business momentum to continue.
• DecisionDx SCC Coverage: No formal timeline for a draft LCD or PAC meeting, but a draft is expected within the next quarter or two; full revenue recovery is modeled for 2028.
• ASPs: Current ASP levels are considered durable and reflect a favorable patient mix; no immediate incremental upside is modeled, but management is open to future wins.
• Moderna Vaccine: Potential long-term growth driver for DecisionDx Melanoma if personalized cancer vaccines move to earlier-stage patient populations currently tested by Castle.
• Sales Team Size: No immediate plans for further expansion; current teams are viewed as sufficient to sustain growth through 2027.

Other Key Points:

• A new decision modeling study was published in September demonstrating that TissueCypher-guided care nearly doubled appropriate escalation of care for high-risk patients while reducing unnecessary procedures.
• The company reiterated its commitment to serving patients and clinicians, linking financial success directly to clinical outcomes.
• Stock-based compensation expense was $11.2 million for the quarter, slightly lower than the prior year.
• The company did not provide specific 2027 revenue guidance, focusing instead on EBITDA positivity and organic growth trends.